Daily Derm Times: April 24, 2025

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Exclusive: Outgoing AAD President Seemal Desai, MD, FAAD, on the 3 Issues That Will Shape Dermatology in 2025 (& Beyond)

Dermatology undergoes rapid transformation with new therapies, but faces challenges in payment reform, certification awareness, and balancing technology with patient care.

Poly-l-Lysine Biovectors with Vitamins A and C Effective for Atopic Dermatitis

DLQI score reduced by 61.8% and SCORAD score reduced by 41.8% in patients after 28 days of treatment.

AbbVie Files BLA for TrenibotE in Glabellar Lines

AbbVie seeks FDA approval for TrenibotE, a first-in-class botulinum toxin offering fast onset and short duration for glabellar lines.

Managing Wound Risks in Patients on TKIs

Explore how tyrosine kinase inhibitors hinder wound healing, revealing critical insights for clinicians in dermatology and oncology.

Upadacitinib Outpaces Dupilumab in Rapid AD Symptom Control

Discover how upadacitinib outperforms dupilumab in providing rapid itch relief for moderate-to-severe atopic dermatitis in a recent AAD study.

Novel Microneedle Radiofrequency Device is Safe for Horizontal Neck Wrinkles

A pilot study reveals a dual-length microneedle RF device effectively reduces neck wrinkles by 35%, enhancing skin hydration and elasticity with minimal downtime.

Stopping Adjuvant Immunotherapy Early May Not Worsen Outcomes in Resected Metastatic Melanoma

New research reveals that early discontinuation of adjuvant immunotherapy for melanoma does not lead to worse outcomes.